Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -9.80%69.49B | 0.01%45.57B | 31.42%16.87B | 2.55%110.71B | 6.12%77.04B | -7.27%45.56B | -45.34%12.83B | 4.99%107.96B | -8.77%72.6B | -10.72%49.14B |
| Operating income | -9.80%69.49B | 0.01%45.57B | 31.42%16.87B | 2.55%110.71B | 6.12%77.04B | -7.27%45.56B | -45.34%12.83B | 4.99%107.96B | -8.77%72.6B | -10.72%49.14B |
| Operating expenses | 9.68%-62.61B | 0.91%-40.61B | -29.42%-15.95B | -3.29%-99.13B | -7.06%-69.31B | 6.06%-40.98B | 42.17%-12.33B | -9.72%-95.97B | 3.48%-64.74B | 6.48%-43.62B |
| Gross profit | -10.88%6.88B | 8.20%4.96B | 80.11%912.77M | -3.39%11.58B | -1.64%7.72B | -16.91%4.58B | -76.61%506.79M | -21.96%11.98B | -37.19%7.85B | -34.27%5.51B |
| Selling expenses | -4.28%-1.77B | -1.88%-1.14B | -8.01%-555.99M | 2.70%-2.33B | 7.26%-1.7B | 2.22%-1.12B | 11.69%-514.76M | -1.18%-2.4B | -4.21%-1.83B | -0.91%-1.14B |
| Administrative expenses | -2.59%-4.84B | -1.32%-3.42B | -6.83%-1.69B | -1.26%-6.65B | -8.55%-4.72B | -3.41%-3.38B | -7.11%-1.59B | 5.64%-6.57B | 9.04%-4.35B | -1.32%-3.27B |
| Research and development expenses | -0.72%-559.5M | -18.38%-356.67M | -13.04%-150.45M | -25.60%-665.89M | -16.71%-555.5M | -15.44%-301.29M | -27.56%-133.09M | -29.27%-530.17M | -12.47%-475.98M | -32.88%-261M |
| Profit from asset sales | 76.41%1.79B | -79.50%204.98M | -55.79%20.24M | 4.37%1.2B | 55.96%1.01B | 61.33%999.79M | -73.46%45.78M | -12.09%1.15B | 1,327.75%650.49M | 1,291.51%619.72M |
| Revaluation surplus | -18.73%182.6M | -12.00%184.85M | -40.74%14.19M | -36.70%738.5M | -33.64%224.69M | -37.61%210.06M | 82.80%23.95M | 100.11%1.17B | 5.56%338.62M | 9.02%336.7M |
| -Changes in the fair value of other assets | -18.73%182.6M | -12.00%184.85M | -40.74%14.19M | -36.70%738.5M | -33.64%224.69M | -37.61%210.06M | 82.80%23.95M | 100.11%1.17B | 5.56%338.62M | 9.02%336.7M |
| Impairment and provision | -131.80%-89.69M | 70.77%-113.52M | 41.84%54.43M | 49.25%-1.01B | 653.16%282.02M | -158.69%-388.41M | 284.18%38.38M | -54.74%-1.98B | 73.24%-50.98M | -33.80%-150.14M |
| -Other impairment is provision | -131.80%-89.69M | 70.77%-113.52M | 41.84%54.43M | 49.25%-1.01B | 653.16%282.02M | -158.69%-388.41M | 284.18%38.38M | -54.74%-1.98B | 73.24%-50.98M | -33.80%-150.14M |
| Special items of operating profit | 9.93%690.12M | 39.72%558.84M | -1.70%399.22M | 136.47%1.67B | 13.72%627.78M | 10.10%399.96M | 338.88%406.14M | -18.45%705.26M | -20.17%552.06M | -15.89%363.26M |
| Operating profit | -40.83%1.24B | -95.21%20.82M | -7.38%-1.32B | 30.76%3.18B | 0.05%2.1B | -73.62%434.72M | -2,433.69%-1.23B | -58.19%2.43B | -60.39%2.1B | -55.38%1.65B |
| Financing cost | 2.61%-2.22B | 8.00%-1.46B | 12.64%-682.14M | -22.93%-2.8B | -10.03%-2.28B | -22.35%-1.58B | -12.31%-780.83M | 15.35%-2.28B | -5.11%-2.08B | 14.53%-1.3B |
| Adjustment items of earning before tax | -25.22%146.28M | 34.34%106.55M | 74.50%46.29M | -48.97%73.5M | 140.57%195.61M | 9.25%79.32M | 44.81%26.53M | -26.52%144.02M | -92.79%81.31M | -93.93%72.6M |
| Earning before tax | -7,631.43%-835.98M | -24.28%-1.33B | 1.38%-1.96B | 51.84%456.1M | -89.32%11.1M | -351.47%-1.07B | -173.87%-1.99B | -90.97%300.39M | -97.66%103.97M | -87.39%425.68M |
| Tax | -27.06%-1.11B | 14.81%-578.49M | -80.26%-168.11M | -25.35%-1.99B | -67.68%-876.72M | -65.22%-679.09M | 20.68%-93.26M | -0.17%-1.59B | 61.46%-522.85M | 56.96%-411.02M |
| After-tax profit from continuing operations | -125.26%-1.95B | -9.11%-1.91B | -2.28%-2.13B | -19.17%-1.53B | -106.65%-865.62M | -12,035.15%-1.75B | -146.74%-2.08B | -173.99%-1.29B | -113.54%-418.88M | -99.39%14.66M |
| Earning after tax | -125.26%-1.95B | -9.11%-1.91B | -2.28%-2.13B | -19.17%-1.53B | -106.65%-865.62M | -12,035.15%-1.75B | -146.74%-2.08B | -173.99%-1.29B | -113.54%-418.88M | -99.39%14.66M |
| Minority profit | -22.33%-524.87M | 56.17%-413.28M | -15.73%-893.21M | 25.42%-979.05M | 0.10%-429.07M | -138.46%-942.87M | -50.89%-771.81M | -348.98%-1.31B | -156.16%-429.49M | -167.71%-395.4M |
| Profit attributable to shareholders | -226.44%-1.43B | -85.40%-1.5B | 5.65%-1.23B | -2,297.55%-555.16M | -4,212.65%-436.54M | -296.72%-806.67M | -294.57%-1.31B | -97.92%25.26M | -99.54%10.61M | -77.66%410.06M |
| Basic earnings per share | -224.39%-0.133 | -58.33%-0.19 | 0.00%-0.12 | -87.50%-0.15 | -4,200.00%-0.041 | -4,900.00%-0.12 | -300.00%-0.12 | -366.67%-0.08 | 0.001 | -98.08%0.0025 |
| Diluted earnings per share | -224.39%-0.133 | -58.33%-0.19 | 0.00%-0.12 | -87.50%-0.15 | -4,200.00%-0.041 | -4,900.00%-0.12 | -300.00%-0.12 | -366.67%-0.08 | 0.001 | -98.08%0.0025 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.